Drug Trial Radar · NCT04169997
A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
404
Actual
Start
Dec 24, 2019
Primary completion
Mar 16, 2023
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Impact Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IMP4297 is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of IMP4297 for Maintenance Treatment
Conditions
- Ovarian Cancer
Interventions
IMP4927Drug
IMP4297 tablet.The starting dose from 100mg QD
PlacebosDrug
Placebos tablet.The starting dose from 100mg QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: Approximately 42 months since the first subject enrolled
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guanzhou, Guangdong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.